Stimulation of urokinase-type plasminogen activator receptor expression by PMA requires JNK1-dependent and -independent signaling modules View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

1998-07-17

AUTHORS

R Gum, J Juarez, H Allgayer, A Mazar, Y Wang, D Boyd

ABSTRACT

The urokinase-type plasminogen activator receptor (u-PAR) has been implicated in tumor progression, and previous studies have shown that the expression of this gene is strongly up-regulated by PMA. Although the signaling mechanism by which PMA modulates u-PAR expression is not known, the effect of this phorbol ester on the expression of other genes has been ascribed to activation of the c-Raf-1-ERK signaling pathway. However, in the current study we examined an alternate possibility that the inductive effect of PMA on u-PAR expression also required a JNK1-dependent signaling cascade usually associated with stress-inducing stimuli. PMA treatment of the u-PAR-deficient OVCAR-3 ovarian cancer cells, which contain low JNK activities, resulted in a rapid (5 min) increase in JNK activity. Maximal JNK activity (12-fold induction) occurred after 30 min; this preceding the earliest detected rise in u-PAR protein (2 h). Dose-response studies with PMA also indicated that the increased JNK activity was tightly correlated with elevated u-PAR protein levels. The stimulation of u-PAR promoter activity by PMA required an intact upstream AP-1 motif (−184) and in PMA-treated cells this motif was bound with c-Jun as indicated from mobility shift assays. PMA up-regulated the c-Jun trans acting activity as indicated by the higher activity of a GAL4-regulated luciferase reporter in phorbol-ester-treated cells co-transfected with an expression vector encoding the c-Jun transactivation domain fused to the GAL4 DNA-binding domain. The ability of PMA to stimulate u-PAR promoter activity was effectively titrated out by the co-expression of either a kinase-defective JNK1 or a dominant negative MEKK1 the latter being an upstream activator of JNK1. Conversely, u-PAR promoter activity was stimulated by the co-expression of a constitutively active MEKK1 and this induction was antagonized by the inclusion of the kinase-defective JNK1 plasmid. We also determined the biological significance of the JNK1-dependent signaling cascade in regulating u-PAR promoter activity by c-Ha-ras since this oncogene is activated and/or overexpressed in a variety of tumors including ovarian cancer. Transfection of an activated c-Ha-ras into OVCAR-3 cells stimulated u-PAR promoter activity over 20-fold and this could be countered by the individual expression of dominant negative expression constructs to Rac-1, MEKK1 or JNK1. Taken together, these data suggest that the PMA- or c-Ha-Ras-dependent stimulation of u-PAR gene expression requires a JNK1-dependent signaling module and that, at least for PMA, the concurrent stimulation of a JNK1-independent signaling module is also required. Thus, caution should be exercised in invoking linear signaling modules to account for the regulation of inducible gene expression. More... »

PAGES

213-225

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/sj.onc.1201917

DOI

http://dx.doi.org/10.1038/sj.onc.1201917

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1017347102

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/9674706


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Calcium-Calmodulin-Dependent Protein Kinases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dose-Response Relationship, Drug", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Flavonoids", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "JNK Mitogen-Activated Protein Kinases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mitogen-Activated Protein Kinases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Nerve Tissue Proteins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Promoter Regions, Genetic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Protein-Serine-Threonine Kinases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Proto-Oncogene Proteins c-raf", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Proto-Oncogene Proteins p21(ras)", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Receptors, Cell Surface", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Receptors, Urokinase Plasminogen Activator", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Signal Transduction", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tetradecanoylphorbol Acetate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Transcription Factor AP-1", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Transcription, Genetic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Up-Regulation", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Molecular Immunology, SmithKline Beecham, King of Prussia, 19406, Pennsylvania, USA", 
          "id": "http://www.grid.ac/institutes/grid.418019.5", 
          "name": [
            "Department of Molecular Immunology, SmithKline Beecham, King of Prussia, 19406, Pennsylvania, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gum", 
        "givenName": "R", 
        "id": "sg:person.01077711452.40", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01077711452.40"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Tumor Biology/Head & Neck Surgery, M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, Texas, USA", 
          "id": "http://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Tumor Biology/Head & Neck Surgery, M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, Texas, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Juarez", 
        "givenName": "J", 
        "id": "sg:person.01017445730.26", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01017445730.26"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Tumor Biology/Head & Neck Surgery, M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, Texas, USA", 
          "id": "http://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Tumor Biology/Head & Neck Surgery, M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, Texas, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Allgayer", 
        "givenName": "H", 
        "id": "sg:person.01014122003.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01014122003.46"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Angstrom Pharmaceuticals, 11772 Sorrento Valley Road, #101, San Diego, California, USA", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Angstrom Pharmaceuticals, 11772 Sorrento Valley Road, #101, San Diego, California, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mazar", 
        "givenName": "A", 
        "id": "sg:person.01072434141.27", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01072434141.27"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Renal Medicine, Westmead Hospital, The University of Sydney, Westmead NSW 2145, Sydney, Australia", 
          "id": "http://www.grid.ac/institutes/grid.413252.3", 
          "name": [
            "Department of Renal Medicine, Westmead Hospital, The University of Sydney, Westmead NSW 2145, Sydney, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wang", 
        "givenName": "Y", 
        "id": "sg:person.0747064230.39", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0747064230.39"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Tumor Biology/Head & Neck Surgery, M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, Texas, USA", 
          "id": "http://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Tumor Biology/Head & Neck Surgery, M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, Texas, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Boyd", 
        "givenName": "D", 
        "id": "sg:person.01145207075.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01145207075.25"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "1998-07-17", 
    "datePublishedReg": "1998-07-17", 
    "description": "The urokinase-type plasminogen activator receptor (u-PAR) has been implicated in tumor progression, and previous studies have shown that the expression of this gene is strongly up-regulated by PMA. Although the signaling mechanism by which PMA modulates u-PAR expression is not known, the effect of this phorbol ester on the expression of other genes has been ascribed to activation of the c-Raf-1-ERK signaling pathway. However, in the current study we examined an alternate possibility that the inductive effect of PMA on u-PAR expression also required a JNK1-dependent signaling cascade usually associated with stress-inducing stimuli. PMA treatment of the u-PAR-deficient OVCAR-3 ovarian cancer cells, which contain low JNK activities, resulted in a rapid (5\u2009min) increase in JNK activity. Maximal JNK activity (12-fold induction) occurred after 30\u2009min; this preceding the earliest detected rise in u-PAR protein (2\u2009h). Dose-response studies with PMA also indicated that the increased JNK activity was tightly correlated with elevated u-PAR protein levels. The stimulation of u-PAR promoter activity by PMA required an intact upstream AP-1 motif (\u2212184) and in PMA-treated cells this motif was bound with c-Jun as indicated from mobility shift assays. PMA up-regulated the c-Jun trans acting activity as indicated by the higher activity of a GAL4-regulated luciferase reporter in phorbol-ester-treated cells co-transfected with an expression vector encoding the c-Jun transactivation domain fused to the GAL4 DNA-binding domain. The ability of PMA to stimulate u-PAR promoter activity was effectively titrated out by the co-expression of either a kinase-defective JNK1 or a dominant negative MEKK1 the latter being an upstream activator of JNK1. Conversely, u-PAR promoter activity was stimulated by the co-expression of a constitutively active MEKK1 and this induction was antagonized by the inclusion of the kinase-defective JNK1 plasmid. We also determined the biological significance of the JNK1-dependent signaling cascade in regulating u-PAR promoter activity by c-Ha-ras since this oncogene is activated and/or overexpressed in a variety of tumors including ovarian cancer. Transfection of an activated c-Ha-ras into OVCAR-3 cells stimulated u-PAR promoter activity over 20-fold and this could be countered by the individual expression of dominant negative expression constructs to Rac-1, MEKK1 or JNK1. Taken together, these data suggest that the PMA- or c-Ha-Ras-dependent stimulation of u-PAR gene expression requires a JNK1-dependent signaling module and that, at least for PMA, the concurrent stimulation of a JNK1-independent signaling module is also required. Thus, caution should be exercised in invoking linear signaling modules to account for the regulation of inducible gene expression.", 
    "genre": "article", 
    "id": "sg:pub.10.1038/sj.onc.1201917", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.2440396", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.2471333", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.2490273", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1097543", 
        "issn": [
          "0950-9232", 
          "1476-5594"
        ], 
        "name": "Oncogene", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "17"
      }
    ], 
    "keywords": [
      "PAR promoter activity", 
      "promoter activity", 
      "JNK activity", 
      "urokinase-type plasminogen activator receptor", 
      "Ha-ras", 
      "dominant negative expression constructs", 
      "GAL4 DNA-binding domain", 
      "gene expression", 
      "dominant negative MEKK1", 
      "Jun transactivation domain", 
      "DNA-binding domain", 
      "inducible gene expression", 
      "mobility shift assays", 
      "AP-1 motif", 
      "low JNK activity", 
      "urokinase-type plasminogen activator receptor (uPAR) expression", 
      "plasminogen activator receptor expression", 
      "PAR gene expression", 
      "OVCAR-3 ovarian cancer cells", 
      "PAR proteins", 
      "active MEKK1", 
      "stress-inducing stimuli", 
      "signaling modules", 
      "transactivation domain", 
      "upstream activator", 
      "shift assays", 
      "expression constructs", 
      "ability of PMA", 
      "PAR expression", 
      "ovarian cancer cells", 
      "signaling mechanism", 
      "expression vector", 
      "MEKK1", 
      "JNK1", 
      "luciferase reporter", 
      "plasminogen activator receptor", 
      "biological significance", 
      "PMA treatment", 
      "phorbol ester", 
      "OVCAR-3 cells", 
      "protein levels", 
      "cancer cells", 
      "Rac-1", 
      "dependent stimulation", 
      "genes", 
      "activator receptor", 
      "expression", 
      "tumor progression", 
      "motif", 
      "PMA", 
      "variety of tumors", 
      "cells", 
      "GAL4", 
      "domain", 
      "oncogene", 
      "reporter", 
      "protein", 
      "activity", 
      "plasmid", 
      "transfection", 
      "individual expression", 
      "receptor expression", 
      "activator", 
      "pathway", 
      "regulation", 
      "cascade", 
      "high activity", 
      "stimulation", 
      "previous studies", 
      "activation", 
      "induction", 
      "assays", 
      "ovarian cancer", 
      "rapid increase", 
      "receptors", 
      "concurrent stimulation", 
      "inductive effect", 
      "mechanism", 
      "trans", 
      "progression", 
      "constructs", 
      "vector", 
      "dose-response study", 
      "current study", 
      "alternate possibilities", 
      "variety", 
      "ability", 
      "study", 
      "cancer", 
      "module", 
      "levels", 
      "effect", 
      "esters", 
      "stimuli", 
      "significance", 
      "increase", 
      "tumors", 
      "rise", 
      "possibility", 
      "data", 
      "treatment", 
      "caution", 
      "min", 
      "inclusion", 
      "Raf-1-ERK", 
      "PAR-deficient OVCAR-3 ovarian cancer cells", 
      "Maximal JNK activity", 
      "PAR protein levels", 
      "intact upstream AP-1 motif", 
      "upstream AP-1 motif", 
      "Jun trans", 
      "kinase-defective JNK1", 
      "negative MEKK1", 
      "kinase-defective JNK1 plasmid", 
      "JNK1 plasmid", 
      "negative expression constructs", 
      "linear signaling modules", 
      "activator receptor expression"
    ], 
    "name": "Stimulation of urokinase-type plasminogen activator receptor expression by PMA requires JNK1-dependent and -independent signaling modules", 
    "pagination": "213-225", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1017347102"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/sj.onc.1201917"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "9674706"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/sj.onc.1201917", 
      "https://app.dimensions.ai/details/publication/pub.1017347102"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T18:08", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_298.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1038/sj.onc.1201917"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/sj.onc.1201917'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/sj.onc.1201917'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/sj.onc.1201917'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/sj.onc.1201917'


 

This table displays all metadata directly associated to this object as RDF triples.

302 TRIPLES      21 PREDICATES      162 URIs      153 LITERALS      24 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/sj.onc.1201917 schema:about N07ac8b2414e240148436b76a4cf51afd
2 N08c44686ecb2440294979bd983f0d67f
3 N09780748412143fba271bc0e56a862fe
4 N09ea7e312e2e467aa6bd213b4aa68170
5 N0e3ae61470764278882ce2ea57d16480
6 N10e4af1ff0c7472c972fe321067cbbc0
7 N2c4a6d6b4e8243bdad9fd8b3b6d3d81f
8 N5fb5071fa64744eda2634a625a4b7c58
9 N6aa57e827d274e2990c8abe3985c7bc3
10 N6ed536656a5c47d39162b36781e58fb9
11 N724001f71f814d988f8271c7b4748dfb
12 N74859b9aa30e4c139aa008185903a0ab
13 N752fb9ce320d455593068578c13e69e4
14 Nca2d881f74164c9da3848c67ec5fe5bb
15 Ndfdb2ca7f160481fb37b3b9888fb714b
16 Ne2febbe45bd14e39b93f12f4d2736047
17 Nfbf7d6f006104d47952090547e62e583
18 anzsrc-for:11
19 anzsrc-for:1103
20 anzsrc-for:1112
21 schema:author Nb00a63d2aa3f4a0f833c29507af9efd6
22 schema:datePublished 1998-07-17
23 schema:datePublishedReg 1998-07-17
24 schema:description The urokinase-type plasminogen activator receptor (u-PAR) has been implicated in tumor progression, and previous studies have shown that the expression of this gene is strongly up-regulated by PMA. Although the signaling mechanism by which PMA modulates u-PAR expression is not known, the effect of this phorbol ester on the expression of other genes has been ascribed to activation of the c-Raf-1-ERK signaling pathway. However, in the current study we examined an alternate possibility that the inductive effect of PMA on u-PAR expression also required a JNK1-dependent signaling cascade usually associated with stress-inducing stimuli. PMA treatment of the u-PAR-deficient OVCAR-3 ovarian cancer cells, which contain low JNK activities, resulted in a rapid (5 min) increase in JNK activity. Maximal JNK activity (12-fold induction) occurred after 30 min; this preceding the earliest detected rise in u-PAR protein (2 h). Dose-response studies with PMA also indicated that the increased JNK activity was tightly correlated with elevated u-PAR protein levels. The stimulation of u-PAR promoter activity by PMA required an intact upstream AP-1 motif (−184) and in PMA-treated cells this motif was bound with c-Jun as indicated from mobility shift assays. PMA up-regulated the c-Jun trans acting activity as indicated by the higher activity of a GAL4-regulated luciferase reporter in phorbol-ester-treated cells co-transfected with an expression vector encoding the c-Jun transactivation domain fused to the GAL4 DNA-binding domain. The ability of PMA to stimulate u-PAR promoter activity was effectively titrated out by the co-expression of either a kinase-defective JNK1 or a dominant negative MEKK1 the latter being an upstream activator of JNK1. Conversely, u-PAR promoter activity was stimulated by the co-expression of a constitutively active MEKK1 and this induction was antagonized by the inclusion of the kinase-defective JNK1 plasmid. We also determined the biological significance of the JNK1-dependent signaling cascade in regulating u-PAR promoter activity by c-Ha-ras since this oncogene is activated and/or overexpressed in a variety of tumors including ovarian cancer. Transfection of an activated c-Ha-ras into OVCAR-3 cells stimulated u-PAR promoter activity over 20-fold and this could be countered by the individual expression of dominant negative expression constructs to Rac-1, MEKK1 or JNK1. Taken together, these data suggest that the PMA- or c-Ha-Ras-dependent stimulation of u-PAR gene expression requires a JNK1-dependent signaling module and that, at least for PMA, the concurrent stimulation of a JNK1-independent signaling module is also required. Thus, caution should be exercised in invoking linear signaling modules to account for the regulation of inducible gene expression.
25 schema:genre article
26 schema:inLanguage en
27 schema:isAccessibleForFree true
28 schema:isPartOf N7023cb09feb749ff80f5c5b0649c5cb4
29 N757691aacc774fcfa4cfd946147e4789
30 sg:journal.1097543
31 schema:keywords AP-1 motif
32 DNA-binding domain
33 GAL4
34 GAL4 DNA-binding domain
35 Ha-ras
36 JNK activity
37 JNK1
38 JNK1 plasmid
39 Jun trans
40 Jun transactivation domain
41 MEKK1
42 Maximal JNK activity
43 OVCAR-3 cells
44 OVCAR-3 ovarian cancer cells
45 PAR expression
46 PAR gene expression
47 PAR promoter activity
48 PAR protein levels
49 PAR proteins
50 PAR-deficient OVCAR-3 ovarian cancer cells
51 PMA
52 PMA treatment
53 Rac-1
54 Raf-1-ERK
55 ability
56 ability of PMA
57 activation
58 activator
59 activator receptor
60 activator receptor expression
61 active MEKK1
62 activity
63 alternate possibilities
64 assays
65 biological significance
66 cancer
67 cancer cells
68 cascade
69 caution
70 cells
71 concurrent stimulation
72 constructs
73 current study
74 data
75 dependent stimulation
76 domain
77 dominant negative MEKK1
78 dominant negative expression constructs
79 dose-response study
80 effect
81 esters
82 expression
83 expression constructs
84 expression vector
85 gene expression
86 genes
87 high activity
88 inclusion
89 increase
90 individual expression
91 inducible gene expression
92 induction
93 inductive effect
94 intact upstream AP-1 motif
95 kinase-defective JNK1
96 kinase-defective JNK1 plasmid
97 levels
98 linear signaling modules
99 low JNK activity
100 luciferase reporter
101 mechanism
102 min
103 mobility shift assays
104 module
105 motif
106 negative MEKK1
107 negative expression constructs
108 oncogene
109 ovarian cancer
110 ovarian cancer cells
111 pathway
112 phorbol ester
113 plasmid
114 plasminogen activator receptor
115 plasminogen activator receptor expression
116 possibility
117 previous studies
118 progression
119 promoter activity
120 protein
121 protein levels
122 rapid increase
123 receptor expression
124 receptors
125 regulation
126 reporter
127 rise
128 shift assays
129 signaling mechanism
130 signaling modules
131 significance
132 stimulation
133 stimuli
134 stress-inducing stimuli
135 study
136 trans
137 transactivation domain
138 transfection
139 treatment
140 tumor progression
141 tumors
142 upstream AP-1 motif
143 upstream activator
144 urokinase-type plasminogen activator receptor
145 urokinase-type plasminogen activator receptor (uPAR) expression
146 variety
147 variety of tumors
148 vector
149 schema:name Stimulation of urokinase-type plasminogen activator receptor expression by PMA requires JNK1-dependent and -independent signaling modules
150 schema:pagination 213-225
151 schema:productId N03f4a05e8fe2412db1f92f33156cdc8d
152 N08b8df6686584c97a47a4b92552bf2d9
153 N84cd9a65c5f94ab59c686d3702c963da
154 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017347102
155 https://doi.org/10.1038/sj.onc.1201917
156 schema:sdDatePublished 2022-01-01T18:08
157 schema:sdLicense https://scigraph.springernature.com/explorer/license/
158 schema:sdPublisher N0b984c262e514946a93c4e17cd76548f
159 schema:url https://doi.org/10.1038/sj.onc.1201917
160 sgo:license sg:explorer/license/
161 sgo:sdDataset articles
162 rdf:type schema:ScholarlyArticle
163 N03f4a05e8fe2412db1f92f33156cdc8d schema:name pubmed_id
164 schema:value 9674706
165 rdf:type schema:PropertyValue
166 N07ac8b2414e240148436b76a4cf51afd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Proto-Oncogene Proteins p21(ras)
168 rdf:type schema:DefinedTerm
169 N08b8df6686584c97a47a4b92552bf2d9 schema:name dimensions_id
170 schema:value pub.1017347102
171 rdf:type schema:PropertyValue
172 N08c44686ecb2440294979bd983f0d67f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
173 schema:name JNK Mitogen-Activated Protein Kinases
174 rdf:type schema:DefinedTerm
175 N09780748412143fba271bc0e56a862fe schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name Proto-Oncogene Proteins c-raf
177 rdf:type schema:DefinedTerm
178 N09ea7e312e2e467aa6bd213b4aa68170 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
179 schema:name Promoter Regions, Genetic
180 rdf:type schema:DefinedTerm
181 N0b984c262e514946a93c4e17cd76548f schema:name Springer Nature - SN SciGraph project
182 rdf:type schema:Organization
183 N0e3ae61470764278882ce2ea57d16480 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
184 schema:name Signal Transduction
185 rdf:type schema:DefinedTerm
186 N10e4af1ff0c7472c972fe321067cbbc0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
187 schema:name Receptors, Urokinase Plasminogen Activator
188 rdf:type schema:DefinedTerm
189 N2c4a6d6b4e8243bdad9fd8b3b6d3d81f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
190 schema:name Transcription, Genetic
191 rdf:type schema:DefinedTerm
192 N36a855b81f064ae182bf1b6b2e6d87bd rdf:first sg:person.01014122003.46
193 rdf:rest Ncd583b6a9a484940898d421209e52938
194 N513626a8c6a64e038c143e6259d99807 rdf:first sg:person.01017445730.26
195 rdf:rest N36a855b81f064ae182bf1b6b2e6d87bd
196 N5d69cc0cef974cd08b233141bcc7c49c rdf:first sg:person.0747064230.39
197 rdf:rest N74f6195e9fd7410a9d11ef0233457cf6
198 N5fb5071fa64744eda2634a625a4b7c58 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
199 schema:name Protein-Serine-Threonine Kinases
200 rdf:type schema:DefinedTerm
201 N6aa57e827d274e2990c8abe3985c7bc3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
202 schema:name Transcription Factor AP-1
203 rdf:type schema:DefinedTerm
204 N6ed536656a5c47d39162b36781e58fb9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
205 schema:name Dose-Response Relationship, Drug
206 rdf:type schema:DefinedTerm
207 N7023cb09feb749ff80f5c5b0649c5cb4 schema:issueNumber 2
208 rdf:type schema:PublicationIssue
209 N724001f71f814d988f8271c7b4748dfb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
210 schema:name Nerve Tissue Proteins
211 rdf:type schema:DefinedTerm
212 N74859b9aa30e4c139aa008185903a0ab schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
213 schema:name Mitogen-Activated Protein Kinases
214 rdf:type schema:DefinedTerm
215 N74f6195e9fd7410a9d11ef0233457cf6 rdf:first sg:person.01145207075.25
216 rdf:rest rdf:nil
217 N752fb9ce320d455593068578c13e69e4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
218 schema:name Tetradecanoylphorbol Acetate
219 rdf:type schema:DefinedTerm
220 N757691aacc774fcfa4cfd946147e4789 schema:volumeNumber 17
221 rdf:type schema:PublicationVolume
222 N84cd9a65c5f94ab59c686d3702c963da schema:name doi
223 schema:value 10.1038/sj.onc.1201917
224 rdf:type schema:PropertyValue
225 Nb00a63d2aa3f4a0f833c29507af9efd6 rdf:first sg:person.01077711452.40
226 rdf:rest N513626a8c6a64e038c143e6259d99807
227 Nca2d881f74164c9da3848c67ec5fe5bb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
228 schema:name Flavonoids
229 rdf:type schema:DefinedTerm
230 Ncd583b6a9a484940898d421209e52938 rdf:first sg:person.01072434141.27
231 rdf:rest N5d69cc0cef974cd08b233141bcc7c49c
232 Ndfdb2ca7f160481fb37b3b9888fb714b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
233 schema:name Calcium-Calmodulin-Dependent Protein Kinases
234 rdf:type schema:DefinedTerm
235 Ne2febbe45bd14e39b93f12f4d2736047 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
236 schema:name Receptors, Cell Surface
237 rdf:type schema:DefinedTerm
238 Nfbf7d6f006104d47952090547e62e583 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
239 schema:name Up-Regulation
240 rdf:type schema:DefinedTerm
241 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
242 schema:name Medical and Health Sciences
243 rdf:type schema:DefinedTerm
244 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
245 schema:name Clinical Sciences
246 rdf:type schema:DefinedTerm
247 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
248 schema:name Oncology and Carcinogenesis
249 rdf:type schema:DefinedTerm
250 sg:grant.2440396 http://pending.schema.org/fundedItem sg:pub.10.1038/sj.onc.1201917
251 rdf:type schema:MonetaryGrant
252 sg:grant.2471333 http://pending.schema.org/fundedItem sg:pub.10.1038/sj.onc.1201917
253 rdf:type schema:MonetaryGrant
254 sg:grant.2490273 http://pending.schema.org/fundedItem sg:pub.10.1038/sj.onc.1201917
255 rdf:type schema:MonetaryGrant
256 sg:journal.1097543 schema:issn 0950-9232
257 1476-5594
258 schema:name Oncogene
259 schema:publisher Springer Nature
260 rdf:type schema:Periodical
261 sg:person.01014122003.46 schema:affiliation grid-institutes:grid.240145.6
262 schema:familyName Allgayer
263 schema:givenName H
264 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01014122003.46
265 rdf:type schema:Person
266 sg:person.01017445730.26 schema:affiliation grid-institutes:grid.240145.6
267 schema:familyName Juarez
268 schema:givenName J
269 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01017445730.26
270 rdf:type schema:Person
271 sg:person.01072434141.27 schema:affiliation grid-institutes:None
272 schema:familyName Mazar
273 schema:givenName A
274 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01072434141.27
275 rdf:type schema:Person
276 sg:person.01077711452.40 schema:affiliation grid-institutes:grid.418019.5
277 schema:familyName Gum
278 schema:givenName R
279 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01077711452.40
280 rdf:type schema:Person
281 sg:person.01145207075.25 schema:affiliation grid-institutes:grid.240145.6
282 schema:familyName Boyd
283 schema:givenName D
284 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01145207075.25
285 rdf:type schema:Person
286 sg:person.0747064230.39 schema:affiliation grid-institutes:grid.413252.3
287 schema:familyName Wang
288 schema:givenName Y
289 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0747064230.39
290 rdf:type schema:Person
291 grid-institutes:None schema:alternateName Angstrom Pharmaceuticals, 11772 Sorrento Valley Road, #101, San Diego, California, USA
292 schema:name Angstrom Pharmaceuticals, 11772 Sorrento Valley Road, #101, San Diego, California, USA
293 rdf:type schema:Organization
294 grid-institutes:grid.240145.6 schema:alternateName Department of Tumor Biology/Head & Neck Surgery, M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, Texas, USA
295 schema:name Department of Tumor Biology/Head & Neck Surgery, M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, Texas, USA
296 rdf:type schema:Organization
297 grid-institutes:grid.413252.3 schema:alternateName Department of Renal Medicine, Westmead Hospital, The University of Sydney, Westmead NSW 2145, Sydney, Australia
298 schema:name Department of Renal Medicine, Westmead Hospital, The University of Sydney, Westmead NSW 2145, Sydney, Australia
299 rdf:type schema:Organization
300 grid-institutes:grid.418019.5 schema:alternateName Department of Molecular Immunology, SmithKline Beecham, King of Prussia, 19406, Pennsylvania, USA
301 schema:name Department of Molecular Immunology, SmithKline Beecham, King of Prussia, 19406, Pennsylvania, USA
302 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...